Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2019-07-12

Last Posted Date: 2024-04-03

Lead Sponsor: Pfizer

Target Recruit Count: 1057

Registration Number: NCT04018001

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Participants

Interventions: Drug: PF-06651600 30 mg

First Posted Date: 2019-07-11

Last Posted Date: 2021-04-08

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT04016077

Locations: 🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Long-Term PF-06651600 for the Treatment of Alopecia Areata

Phase 3

Active, not recruiting

Conditions: Alopecia Areata

Interventions: Drug: PF-06651600
Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine

First Posted Date: 2019-07-05

Last Posted Date: 2025-04-23

Lead Sponsor: Pfizer

Target Recruit Count: 1052

Registration Number: NCT04006457

Locations: 🇺🇸
The University of Alabama at Birmingham Hosptial Outreach Lab, Birmingham, Alabama, United States
🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
The University of Alabama at Birmingham, Department of Dermatology, Birmingham, Alabama, United States

and more 140 locations

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PF-06651600

First Posted Date: 2019-07-02

Last Posted Date: 2019-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04004663

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Be-bru, Belgium

Changes of Depression After First-year of Tofacitinib in RA Patients

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2019-06-20

Last Posted Date: 2025-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 73

Registration Number: NCT03992781

Locations: 🇨🇿
Thomayerova nemocnice, Prague, Czech Republic, Czechia
🇨🇿
Rheuma s.r.o., Breclav, Czechia
🇨🇿
Revmatologie s.r.o., Brno, Czechia

and more 3 locations

A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: PF-06882961

First Posted Date: 2019-06-13

Last Posted Date: 2022-06-30

Lead Sponsor: Pfizer

Target Recruit Count: 412

Registration Number: NCT03985293

Locations: 🇺🇸
Holy Trinity Medical Clinic, Harbor City, California, United States
🇺🇸
Innovative Clinical Research, Inc., Harbor City, California, United States
🇺🇸
Long Beach Clinical Trials Services, Inc., Long Beach, California, United States

and more 78 locations

IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Tofacitinib

First Posted Date: 2019-06-11

Last Posted Date: 2024-09-30

Lead Sponsor: Pfizer

Target Recruit Count: 314

Registration Number: NCT03981900

Locations: 🇫🇷
Centre Hospitalier D'arras, Arras Cedex, France
🇫🇷
Hopital Robert Ballanger, Aulnay Sous Bois, France
🇫🇷
Cabinet Medical, Vincennes, France

and more 49 locations

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D
Drug: Treatment E
Drug: Treatment F
Drug: Treatment G
Drug: Treatment H

First Posted Date: 2019-06-06

Last Posted Date: 2019-11-15

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT03978143

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2019-06-05

Last Posted Date: 2023-06-09

Lead Sponsor: Pfizer

Target Recruit Count: 479

Registration Number: NCT03975790

Locations: 🇺🇸
Pfizer, New York, New York, United States

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Biological: PF-06946860

First Posted Date: 2019-06-05

Last Posted Date: 2020-01-29

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT03974776

Locations: 🇺🇸
Anaheim Clinical Trials LLC-Clinical Research, Anaheim, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy